Welcome to our dedicated page for Recursion Pharmaceuticals news (Ticker: RXRX), a resource for investors and traders seeking the latest updates and insights on Recursion Pharmaceuticals stock.
Recursion Pharmaceuticals, Inc. develops investigational medicines as a clinical-stage TechBio company using the Recursion OS, an AI-native drug discovery and development platform that integrates biology, chemistry, automation, data science and clinical development. Company updates center on wholly owned and partnered programs in oncology, rare disease, neuroscience, immunology and other therapeutic areas.
Recurring announcements cover clinical and preclinical pipeline progress, financial results, platform infrastructure, automated laboratory operations, collaborations and partner milestones. Recursion also reports governance and leadership changes, investor-conference participation and updates tied to named programs such as REC-1245, REC-4881 and REC-4539 when those programs advance through development.
Recursion (Nasdaq: RXRX) reported second quarter 2026 results and major R&D milestones. Genentech exercised the first Validated Target Option in the companies’ neuroscience collaboration, moving a previously unexplored target into a joint small-molecule early discovery program and adding early evidence that Recursion’s AI-native platform can generate biologically validated drug targets.
The company highlighted progress with partners Roche/Genentech and Sanofi, and internal programs REC-4881 (FAP) and REC-7735 (PI3Kα H1047R), with REC-7735’s IND cleared and Phase 1/2 initiation planned for 2H26. Revenue was $7.7 million versus $19.2 million a year ago; net loss narrowed to $131.0 million from $171.9 million. Cash and restricted cash were $556.8 million with an expected runway into early 2028. Research and development and general and administrative expenses both declined year over year, and 2026 cash operating expense guidance was reduced to below $375 million from below $390 million, reflecting additional operating efficiencies.
Recursion (Nasdaq: RXRX) announced it will participate in two upcoming investor conferences: the Bank of America 2026 SMID Cap Executive Insights Event on Tuesday, August 11, 2026, and the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026. Webcasts of Recursion’s presentations will be available in the events section of its investor relations website at ir.recursion.com.
Recursion (Nasdaq: RXRX) reported that on July 27, 2026, its Board Compensation Committee approved inducement restricted stock unit (RSU) awards covering an aggregate 3,234,866 shares of class A common stock for 24 new employees under the 2024 Inducement Equity Incentive Plan.
According to Recursion, the RSUs were granted as material inducements to employment in reliance on Nasdaq Listing Rule 5635(c)(4). Each award vests 1/4 of the shares on the first quarterly vesting date after the one-year anniversary of the vesting commencement date and 1/16 on each subsequent quarterly vesting date, subject to continued employment and the terms of the 2024 Plan and individual grant agreements.
Recursion (Nasdaq: RXRX) announced it will provide business updates and report its second quarter 2026 financial results on Wednesday, August 5, 2026, before U.S. financial markets open.
The company will host a public earnings call on August 5, 2026 at 8:00 AM ET / 6:00 AM MT / 1:00 PM BST, livestreamed via its X, LinkedIn, and YouTube accounts, with questions collected through an online form.
Recursion (Nasdaq: RXRX) announced it will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026.
Webcasts of the appearance will be available in the events section of the Recursion investor relations website at ir.recursion.com.
Recursion (NASDAQ: RXRX) reported that its Board Compensation Committee approved inducement restricted stock unit (RSU) awards on May 26, 2026, covering 2,991,840 class A shares for 33 new employees under its 2024 Inducement Equity Incentive Plan.
RSUs vest over multiple years, subject to continued employment.
Recursion (Nasdaq: RXRX) reported Q1 2026 results and business progress on May 6, 2026. Key clinical highlights include REC-1245 early Phase 1 safety/PK with no DLTs (n=16), REC-4881 Phase 2 polyp reductions (median 43% at Week 13, 53% at Week 25), and first patient dosed in REC-4539. Financials: cash $665.2M (Mar 31, 2026), revenue $6.5M, net loss $117.5M. Company reiterates 2026 operational cash burn <$390M and expects runway into early 2028 without additional financing.
Recursion (NASDAQ: RXRX) announced a board transition: founder Chris Gibson, Ph.D. will complete his current term through June 2026 and will not seek re-election to the board, and will continue with the company as a strategic advisor.
CEO Najat Khan reaffirmed a focus on continuity, the company’s internal and partnered pipeline, and translating its AI-powered platform toward therapeutic impact for shareholders and patients.
Recursion (Nasdaq: RXRX) will report first quarter 2026 business updates and financial results on Wednesday, May 6, 2026, before market open. The company will host a public Earnings Call at 8:00 am ET / 6:00 am MT / 1:00 pm BST and stream live on Recursion's X, LinkedIn, and YouTube accounts. Investors may submit questions via the company form link provided.
Recursion (Nasdaq: RXRX) will participate in two upcoming investor conferences: the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026, and the Bank of America Health Care Conference 2026 on May 12, 2026. Webcasts will be available in the company events section at ir.recursion.com.